Immix Biopharma prices $125M common stock offering at $11 per share

Immix Biopharma, Inc. (Nasdaq: IMMX) priced an underwritten registered offering of 11,363,637 shares of common stock at $11.00 per share, according to a press release statement. The offering is expected to generate $125 million in gross proceeds before underwriting discounts, commissions, and other expenses.

The offering is expected to close on or about September 30, 2026, subject to customary closing conditions. The company said it intends to use the net proceeds to fund development of its NXC-201 drug candidate, as well as for working capital and general corporate purposes.

J.P. Morgan is acting as sole book-running manager for the offering. Participating institutional investors include Eventide Asset Management, Janus Henderson Investors, Ridgeback Capital Investments L.P., and Wellington Management, among others.

The shares are being offered under a shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission on January 9, 2026, and declared effective on January 22, 2026.

Immix Biopharma is a clinical-stage biopharmaceutical company focused on AL Amyloidosis. Its lead candidate, NXC-201, is a BCMA-targeted CAR-T cell therapy currently being evaluated in the U.S. multi-center NEXICART-2 study. NXC-201 holds Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy designation from the FDA, as well as Orphan Drug Designation from both the FDA and the European Medicines Agency.

You May Also Be Interested In

• Accelevation prices IPO at $18 per share on Nasdaq
• Beasley Broadcast raises $5M via direct offering and private placement
• E-Power prices $1.87M registered direct offering of shares